Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?
- 1 August 2002
- journal article
- review article
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 187 (2), 333-339
- https://doi.org/10.1067/mob.2002.125740
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- ACOG Practice Bulletin No. 29: Chronic Hypertension in PregnancyObstetrics & Gynecology, 2001
- Apparent cyclophosphamide (cytoxan) embryopathy: A distinct phenotype?American Journal of Medical Genetics, 1999
- Off‐label prescribingBMJ, 1999
- Practice Parameter: Management Issues for Women with Epilepsy (Summary Statement)Epilepsia, 1998
- Thalidomide: was the tragedy preventable?The Lancet, 1998
- Formed by thalidomide: mass torts as a false cure for toxic exposure.Columbia Law Review, 1997
- Bendectin and birth defects: I. A meta‐analysis of the epidemiologic studiesTeratology, 1994
- Maternal factors, medications, and drug exposure in congenital limb reduction defects.Environmental Health Perspectives, 1993
- Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoidsJournal of the American Academy of Dermatology, 1982
- How the fda determines the “safety” of drugs: Are drugs used in obstetrics really “safe”?Journal of Nurse-Midwifery, 1982